Bax activation by engagement with, then release from, the BH3 binding site of Bcl-xL

Molecular and Cellular Biology

Volumn 31, Issue 4, 2011, Pages 832-844

  Gautier, F ^a,b   Guillemin, Y ^a   Cartron, P F ^a   Gallenne, T ^a   Cauquil, N ^c   Le Diguarher, T ^c   Casara, P ^c   Vallette, F M ^a   Manon, S ^c   Hickman, J A ^d   Geneste, O ^d   Juin, P ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; PEPTIDOMIMETIC AGENT; PROTEIN BAX; PROTEIN BCL XL; PUMA PROTEIN; TERPHENYL DERIVATIVE;

ARTICLE; BINDING SITE; CELL DEATH; CELL SURVIVAL; DRUG ACTIVITY; HUMAN; HUMAN CELL; MITOCHONDRIAL PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

MAMMALIA;

EID: 79251580970     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00161-10     Document Type: Article

References (48)

1. Adams, J. M., and S. Cory. 2007. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26:1324-1337.
2. Amundson, S. A., et al. 2000. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60:6101-6110.
3. Arokium, H., N. Camougrand, F. M. Vallette, and S. Manon. 2004. Studies of the interaction of substituted mutants of BAX with yeast mitochondria reveal that the C-terminal hydrophobic alpha-helix is a second ART sequence and plays a role in the interaction with anti-apoptotic BCL-xL. J. Biol. Chem. 279:52566-52573.
4. Cartron, P. F., et al. 2004. The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol. Cell 16:807-818.
5. Cartron, P. F., L. Oliver, E. Mayat, K. Meflah, and F. M. Vallette. 2004. Impact of pH on Bax alpha conformation, oligomerisation and mitochondrial integration. FEBS Lett. 578:41-46.
6. Cartron, P. F., et al. 2003. The N-terminal end of Bax contains a mitochondrial- targeting signal. J. Biol. Chem. 278:11633-11641.
7. Chang, B. S., et al. 1999. The BH3 domain of Bcl-x(S) is required for inhibition of the antiapoptotic function of Bcl-x(L). Mol. Cell. Biol. 9:6673-6681.
8. Chipuk, J. E., et al. 2008. Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc. Natl. Acad. Sci. U. S. A. 105:20327-20332.
9. Del Gaizo Moore, V., et al. 2007. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest. 117:112-121.
10. Desagher, S., et al. 1999. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J. Cell Biol. 144:891-901.
11. Gallenne, T., et al. 2009. Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J. Cell Biol. 185:279-290.
12. George, N. M., J. J. Evans, and X. Luo. 2007. A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of Bax. Genes Dev. 21:1937-1948.
13. Gillissen, B., et al. 2003. Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO J. 22:3580-3590.
14. Green, D. R., and G. Kroemer. 2004. The pathophysiology of mitochondrial cell death. Science 305:626-629.
15. Hsu, Y. T., K. G. Wolter, and R. J. Youle. 1997. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc. Natl. Acad. Sci. U. S. A. 94:3668-3672.
16. Kim, H., et al. 2006. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8:1348-1358.
17. Konopleva, M., et al. 2006. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375-388.
18. Kutzki, O., et al. 2002. Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J. Am. Chem. Soc. 124:11838-11839.
19. Kuwana, T., et al. 2002. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111:331-342. (Pubitemid 35341388)
20. Lakhani, S. A., et al. 2006. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 311:847-851.
21. Lalier, L., et al. 2007. Bax activation and mitochondrial insertion during apoptosis. Apoptosis 12:887-896. (Pubitemid 46653297)
22. Letai, A. 2009. Puma strikes Bax. J. Cell Biol. 185:189-191.
23. Letai, A., et al. 2002. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2:183-192.
24. Letai, A. G. 2008. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat. Rev. Cancer 8:121-132.
25. Maiuri, M. C., et al. 2007. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J. 26:2527-2539.
26. Manero, F., et al. 2006. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res. 66:2757-2764.
27. Mitsiades, C. S., et al. 2007. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. J. Clin. Endocrinol. Metab. 92:4845-4852.
28. Moreau, C., et al. 2003. Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins. J. Biol. Chem. 278:19426-19435.
29. Muchmore, S. W., et al. 1996. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381:335-341.
30. Oltersdorf, T., et al. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681.
31. Ottilie, S., et al. 1997. Structural and functional complementation of an inactive Bcl-2 mutant by Bax truncation. J. Biol. Chem. 272:16955-16961.
32. Petros, A. M., E. T. Olejniczak, and S. W. Fesik. 2004. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta 1644:83-94.
33. Priault, M., et al. 2003. Investigation of the role of the C-terminus of Bax and of tc-Bid on Bax interaction with yeast mitochondria. Cell Death Differ. 10:1068-1077.
34. Reed, J. C. 2003. Apoptosis-targeted therapies for cancer. Cancer Cell 3:17-22.
35. Schwartz, P. S., et al. 2007. 2-Methoxy antimycin reveals a unique mechanism for Bcl-x(L) inhibition. Mol. Cancer Ther. 6:2073-2080.
36. Suzuki, M., R. J. Youle, and N. Tjandra. 2000. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 103:645-654.
37. Tahir, S. K., et al. 2007. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 67:1176-1183.
38. Terradillos, O., S. Montessuit, D. C. Huang, and J. C. Martinou. 2002. Direct addition of BimL to mitochondria does not lead to cytochrome c release. FEBS Lett. 522:29-34.
39. Tremblais, K., et al. 1999. The C-terminus of bax is not a membrane addressing/anchoring signal. Biochem. Biophys. Res. Commun. 260:582-591.
40. Weber, A., et al. 2007. BimS-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins. J. Cell Biol. 177:625-636.
41. Willis, S. N., and J. M. Adams. 2005. Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 17:617-625.
42. Willis, S. N., et al. 2007. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315:856-859.
43. Yin, H., et al. 2005. Terphenyl-based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. J. Am. Chem. Soc. 127:10191-10196.
44. Youle, R. J., and A. Strasser. 2008. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9:47-59.
45. Yu, J., Z. Wang, K. W. Kinzler, B. Vogelstein, and L. Zhang. 2003. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100:1931-1936.
46. Zha, H., et al. 1996. Structure-function comparisons of the proapoptotic protein Bax in yeast and mammalian cells. Mol. Cell. Biol. 16:6494-6508.
47. Zhou, H., Q. Hou, Y. Chai, and Y. T. Hsu. 2005. Distinct domains of Bcl-XL are involved in Bax and Bad antagonism and in apoptosis inhibition. Exp. Cell Res. 309:316-328.
48. Zhu, Y., et al. 2006. Bax does not have to adopt its final form to drive T cell death. J. Exp. Med. 203:1147-1152.